Lonza

As a leading CDMO enterprise, Lonza is always dedicated to providing comprehensive solutions for the healthcare industry. We serve a diverse range of clients, from emerging biotech companies to global pharmaceutical organizations. We work closely with our clients to translate their innovative therapies into treatment options that improve lives and save lives. Our vision is to become a pioneer and global leader in the CDMO industry, continuously leading the industry with cutting-edge science, intelligent technology, and lean manufacturing.

Founded in 1897, headquartered in Switzerland, Lonza is consistently driven by innovation and actively responds to the rapid development of the global pharmaceutical industry. As one of the pioneers in the CDMO sector, Lonza has deep expertise in pharmaceutical manufacturing. Today, the company has established a global network spanning five continents with over 30 production sites and approximately 20,000 employees. The global team is guided by a common mission: to transform our clients' breakthrough innovations into viable therapies and create the medicines of tomorrow.

Lonza's business structure is designed to meet complex client needs through three synergistic platforms: Biologics Platform, Advanced Synthesis Platform, and Specialized Mode Platform. Our services cover the entire process from early development to drug substance and drug product, and we are at the forefront of both existing and emerging technology areas such as mammalian biologics, small molecules, high-potency active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene therapies. Our one-stop solutions span multiple technology fields to meet clients' needs throughout the entire lifecycle.